NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

DUPILUMAB:新慢性特發性蕁麻疹治療藥分析·市場預測 (∼2030年)

DUPILUMAB- Emerging Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 974747
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
DUPILUMAB:新慢性特發性蕁麻疹治療藥分析·市場預測 (∼2030年) DUPILUMAB- Emerging Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

慢性特發性蕁麻疹治療藥的市場由於廣泛的研究和全球醫療費用的上漲,預計全球治療的市場將在未來幾年內增長,這將使藥物製造商進入更多的市場。

本報告提供新慢性特發性蕁麻疹治療藥物DUPILUMAB的主要7個國家 (美國·德國·法國·義大利·西班牙·英國·日本) 的展望調查,彙整產品概要,作用機制,臨床開發·臨床試驗趨勢,相關法律,專利趨勢,銷售額預測,競爭情形,SWOT分析,分析師的見解等資料。

第1章 藥物概要

  • 產品概要
  • 作用機制
  • 投藥·管理
  • R&D活動
    • 臨床開發
    • 安全性·有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家市場分析
  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第3章 SWOT分析

第4章 分析師的見解

第5章 競爭經營者

第6章 其他新治療藥

第7章 附錄

第8章 購買選擇

目錄
Product Code: DIDM0128

"DUPILUMAB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the DUPILUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor. By blocking the IL-4R alpha subunit, dupilumab inhibits IL-4 and IL-13 cytokine-induced responses, including the release of proinflammatory cytokines, chemokines, and immunoglobulin E.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around DUPILUMAB.
  • The report contains forecasted sales for DUPILUMAB till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Chronic Spontaneous Urticaria.
  • The report also features the SWOT analysis with analyst insights and key findings of DUPILUMAB.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DUPILUMAB Analytical Perspective by DelveInsight

  • In-depth DUPILUMAB Market Assessment

This report provides a detailed market assessment of DUPILUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • DUPILUMAB Clinical Assessment

The report provides the clinical trials information of DUPILUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence DUPILUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Chronic Spontaneous Urticaria are giving market competition to DUPILUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of DUPILUMAB.
  • Our in-depth analysis of the forecasted sales data of DUPILUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPILUMAB.

Key Questions:

  • Which company is developing DUPILUMAB along with the phase of the clinical study?
  • What is the technology utilized in the development of DUPILUMAB?
  • What is the product type, route of administration and mechanism of action of DUPILUMAB?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPILUMAB development?
  • What are the key designations that have been granted to DUPILUMAB?
  • What is the forecasted market scenario of DUPILUMAB?
  • What is the history of DUPILUMAB and what is its future?
  • What is the forecasted sales of DUPILUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to DUPILUMAB?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 DUPILUMAB, Description
  • Table 2 DUPILUMAB, Clinical Trial Description
  • Table 3 DUPILUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of DUPILUMAB
  • Figure 2 Patent Details, DUPILUMAB
  • Figure 3 DUPILUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 DUPILUMAB, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 DUPILUMAB, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 DUPILUMAB, Japan Market Size from 2020 to 2030 (in Millions USD)